Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974261 | 0.89 | FOLH1 (0.43) | FOLH1OPRL1FURIN | |
| SCHEMBL30974507 | 0.87 | FOLH1 (0.44) | FOLH1OPRL1FURIN | |
| SCHEMBL31433255 | 0.85 | SLC6A5 (0.46) | FOLH1NMT2NMT1SLC6A5NOD1 | |
| SCHEMBL31415961 | 0.84 | FOLH1 (0.62) | FOLH1NMT2NMT1SLC6A5CTSC | |
| SCHEMBL29351126 | 0.84 | FOLH1 (0.62) | FOLH1NMT2NMT1SLC6A5CTSC | |
| SCHEMBL29777781 | 0.84 | RAMP3 (0.47) | OPRL1NMT2NMT1 | |
| SCHEMBL29826102 | 0.84 | KEAP1 (0.46) | OPRL1KEAP1 | |
| SCHEMBL30224112 | 0.84 | FOLH1 (0.51) | FOLH1NMT2NMT1SLC6A5NOD1 | |
| SCHEMBL32677410 | 0.84 | FOLH1 (0.46) | FOLH1OPRL1NMT2NMT1SLC6A5 | |
| SCHEMBL29826021 | 0.83 | SLC6A5 (0.45) | FOLH1OPRL1NMT2NMT1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273830-A1 | COMPOUNDS AND METHODS OF USE | Edinburgh Molecular Imaging Limited (GB) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273830-A1 | COMPOUNDS AND METHODS OF USE | VIP, QPCT, CALCRL | FOLH1 17/4885OPRL1 1286/4885NMT2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.